Skip to content

Potential for psychophysical assessments to provide biomarker for AMD progression

Diagnosing AMD as early as possible permits interventional management prior to the onset of any major structural or functional damage. A major goal of disease management is the identification of pre-symptomatic patients using a robust, reproducible and clinically relevant marker for the disease and/or progression of disease. In addition, clinical trials for new experimental AMD treatments may benefit from non-invasive outpatient procedures capable of assessing the impact of a drug on disease progression. Recent clinical data using a combination of 14-Hz flicker assessment and dynamics of the photo-stress recovery (PSR) appear to show that 71% of abnormal AMD cases could be detected using simple standardized and already established methodologies.